Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
FEMS Immunol Med Microbiol ; 48(1): 34-43, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16965350

RESUMEN

Serogroup-specific antibody has been shown to be present in the sera of patients recovering from meningococcal disease, and thus the detection of such antibodies may aid in the confirmation of disease. There are currently no standard methods for measuring meningococcal serogroup B-specific antibody in sera. Here, we report the development of a microsphere-based immunoassay which utilizes colominic acid from Escherichia coli 07:K1 (L):NM to detect immunoglobulin M directed against serogroup B polysaccharide. The serogroup B assay was incorporated into a multiplex assay which also detects serogroup-specific immunoglobulin M for meningococcal serogroups A, C, Y and W-135. Using the method of cross-standardization, serogroup B-specific immunoglobulin M concentrations were assigned to the standard serum CDC 1992. The assay is able to detect increases in specific immunoglobulin M concentrations from acute to convalescent phase serum from serogroup B cases, and can be utilized in conjunction with the previously developed tetraplex immunoglobulin G detection assay for serogroups A, C, Y and W-135.


Asunto(s)
Citometría de Flujo/métodos , Inmunoglobulina M/sangre , Neisseria meningitidis Serogrupo B/inmunología , Polisacáridos Bacterianos/inmunología , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/sangre , Ensayo de Inmunoadsorción Enzimática , Estudios de Evaluación como Asunto , Citometría de Flujo/normas , Humanos , Infecciones Meningocócicas/inmunología , Infecciones Meningocócicas/microbiología , Infecciones Meningocócicas/prevención & control , Microesferas , Neisseria meningitidis Serogrupo B/clasificación , Sensibilidad y Especificidad , Serotipificación
2.
Vaccine ; 23(20): 2623-7, 2005 Apr 08.
Artículo en Inglés | MEDLINE | ID: mdl-15780445

RESUMEN

Though meningococcal conjugate vaccines are effective against serogroup C, there is currently no vaccine solution for serogroup B disease. PorA outer membrane protein (OMP) is a potential serogroup B vaccine candidate. A hexavalent PorA outer membrane vesicle (OMV) vaccine has been evaluated in phase I and II trials with promising results. However, considerable sequence variation occurs in the variable regions (VRs) encoding these serosubtypes. By using five wild type P1.19,15 variant strains we examined the serum bactericidal antibody (SBA) titres from sera collected from toddlers and school children pre- and post-vaccination. The numbers of subjects with SBA titres of <4, 4 and > or = 8 varied greatly between the different strains. This was also reflected when > or = 4-fold rises in SBA titres were examined. This finding in sera from toddlers and school children may have implications for PorA based vaccines.


Asunto(s)
Vacunas Meningococicas/genética , Vacunas Meningococicas/inmunología , Porinas/genética , Porinas/inmunología , Anticuerpos Antibacterianos/análisis , Anticuerpos Antibacterianos/biosíntesis , Especificidad de Anticuerpos , Secuencia de Bases , Actividad Bactericida de la Sangre , Niño , Preescolar , Reacciones Cruzadas , Humanos , Países Bajos , Fenotipo , Vacunas Conjugadas/inmunología
4.
Clin Diagn Lab Immunol ; 11(2): 272-9, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15013975

RESUMEN

A rapid and simple method for the simultaneous quantitation of serum immunoglobulin G (IgG) antibodies specific for Neisseria meningitidis serogroups A, C, Y, and W-135 was developed and evaluated. Four bead sets were generated, each conjugated with one of the meningococcal capsular polysaccharides (A, C, Y, or W-135) and serologically assessed by the use of antimeningococcal international reference sera. Cross-reactivity studies demonstrated no inhibition between monoplex and multiplex assays, and the assay was linear over a 24-fold serum dilution range. Inhibition studies demonstrated that the assay is specific, with <25% heterologous inhibition occurring. The assay was also found to have low intra- and interassay variations and limits of detection < or =650 pg/ml. A comparison of the meningococcal bead assay with the standardized meningococcal enzyme-linked immunosorbent assay showed a good correlation between the IgG concentrations obtained by each assay. The tetraplex assay has the potential to be an important addition to the serologic evaluation of meningococcal capsular polysaccharide conjugate vaccines.


Asunto(s)
Citometría de Flujo/métodos , Infecciones Meningocócicas/diagnóstico , Neisseria meningitidis/inmunología , Anticuerpos Antibacterianos/análisis , Ensayo de Inmunoadsorción Enzimática , Estudios de Evaluación como Asunto , Citometría de Flujo/normas , Humanos , Inmunoglobulina G/análisis , Infecciones Meningocócicas/inmunología , Microesferas , Neisseria meningitidis/aislamiento & purificación , Neisseria meningitidis Serogrupo A/inmunología , Neisseria meningitidis Serogrupo C/inmunología , Neisseria meningitidis Serogrupo W-135/inmunología , Neisseria meningitidis Serogrupo Y/inmunología , Reproducibilidad de los Resultados , Sensibilidad y Especificidad
5.
Vaccine ; 20(19-20): 2592-6, 2002 Jun 07.
Artículo en Inglés | MEDLINE | ID: mdl-12057617

RESUMEN

To date, there are no data assessing the utility of avidity indices as a surrogate marker for the induction of immunological memory following meningococcal serogroup B outer membrane vesicle (OMV) vaccination. We studied infants who had been immunized with three doses of a recombinant hexavalent PorA OMV vaccine at ages 2-4 months, together with a fourth dose at age 12-18 months. A control group had received a single dose of the same vaccine at age 12-18 months. As previously reported, serum bactericidal antibody (SBA) titres increased after each of the first three doses, with a significant increase observed from 6 months post third dose to 1 month post fourth dose. The geometric mean avidity indices (GMAI), against strain H44/76 OMVs, increased from 1 month post first dose to 1 month post third dose. Significant increases in GMAI were observed at 6 months post third dose and again following the fourth dose. At 32-42 months of age, though the SBA titres had returned to post first dose levels, the GMAI remained elevated. No increase in avidity was observed in the control group. Antibody avidity indices are useful laboratory markers for the priming of immunological memory following vaccination with meningococcal serogroup B OMV vaccines.


Asunto(s)
Afinidad de Anticuerpos , Vacunas Meningococicas/administración & dosificación , Porinas/administración & dosificación , Vacunas Sintéticas/administración & dosificación , Anticuerpos Antibacterianos/inmunología , Ensayo de Inmunoadsorción Enzimática , Humanos , Lactante , Vacunas Meningococicas/inmunología , Porinas/inmunología , Reino Unido , Vacunas Sintéticas/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA